Clinical Application of Metagenomic Next-Generation Sequencing-Guided Anti-Infection Strategies in AIDS Patients With Severe Pneumonia and/or Sepsis

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study aims to observe the effectiveness of clinical application in guiding anti-infection treatments in AIDS patients with severe pneumonia and/or sepsis using Metagenomic Next-Generation Sequencing-based technology in the real world

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Confirmed HIV infection;

• Progression to AIDS stage: CD4+ count \<200 cells/ul and/or occurrence of AIDS opportunistic infections;

• Age between 18 and 65 years;

• Meeting the diagnosis of severe pneumonia or septic shock:

‣ The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia;

⁃ The criteria for septic shock refer to the Chinese Society of Critical Care Medicine's Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock (2018).

Locations
Other Locations
China
Linghua Li
RECRUITING
Guangzhou
Time Frame
Start Date: 2023-10-23
Estimated Completion Date: 2027-10-23
Participants
Target number of participants: 400
Treatments
Pathogen metagenomic next-generation sequencing group
This group uses metagenomic next-generation sequencing along with traditional pathogen detection techniques to test for infectious pathogens. The follow-up times are the 1st, 2nd, 3rd, and 4th weeks after being diagnosed with severe pneumonia or sepsis.
Conventional pathogen detection group
This group only used conventional pathogen detection methods for the identification of infectious pathogens. Follow-up was conducted at the 1st, 2nd, 3rd, and 4th weeks after the diagnosis of severe pneumonia or sepsis. The conventional means of pathogen detection include, but are not limited to, fungal serology tests, cryptococcal capsular antigen detection, CMV-DNA tests, sputum smear microscopy, gamma interferon release assays, Xpert MTB/RIF, BLAF culture, blood and bone marrow cultures, radiological examinations, and histopathological examinations.
Sponsors
Leads: Guangzhou 8th People's Hospital

This content was sourced from clinicaltrials.gov